Feldman, D. R., Motzer, R. J., Knezevic, A., Voss, M. H., Lyashchenko, S. K., Park, H., Larson, S. M., Pandit-Taskar, N. (2025). STARLITE 2: Phase 2 study of nivolumab plus
            <sup>177</sup>
            lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab (
            <sup>177</sup>
            Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps4612